Typical group (N=119) | Atypical group (N=40) | |||||||
Univariate analysis* | Multivariate analysis† | Univariate analysis* | Multivariate analysis† | |||||
Factor | Applicable steroid-refractory patient no/applicable patient no (%) | P value | OR (95% CI) | P value | Applicable steroid-refractory patient no /applicable patient no (%) | P value | OR (95% CI) | P value |
Age (>50) | 14/68 (21) | 0.1 | 13/28 (46) | 0.8 | ||||
Male | 18/70 (26) | 0.8 | 8/19 (42) | 0.7 | ||||
Symptoms (three scores)‡ | 19/69 (28) | 0.4 | 1.6 (0.6 to 4.7) | 0.4 | 5/7 (71) | 0.2 | ||
Onset (>50 days)§ | 17/24 (71) | <0.00001 | 16.7 (5.7 to 49.3) | <0.00001 | 16/36 (44) | 1.0 | ||
Initial medium-dosage of corticosteroids | 18/84 (21) | 0.09 | 1.7 (0.6 to 4.8) | 0.4 | 9/28 (32) | 0.01¶ | 3.7 (0.7 to 20) | 0.1 |
Bilaterality | 1/4 (25) | 0.8 | 2/5 (40) | 1.0 | ||||
Myositis | 13/52 (25) | 1.0 | 1/2 (50) | N.D. | ||||
Dacryoadenitis | 2/15 (13) | 0.2 | 3/13 (23) | 0.05 | ||||
Scleritis and optic perineuritis | 8/23 (35) | 0.3 | 0/0. | N.D | ||||
Diffuse (total) | 6/26 (23) | 0.7 | 14/24 (58) | 0.04 | ||||
Diffuse (around eye) | 4/22 (18) | 0.4 | 1/6 (17) | N.D | ||||
Diffuse (intra muscle cone) | 0/1 (0) | N.D | 9/11 (82%) | 0.006 | 8.8 (1.5 to 53) | 0.01 |
High-dosage of corticosteroid treatment was either prednisolone at 1 mg/kg/day with a slow taper or 1000 mg intravenous methylprednisolone once per day for 3 days with prednisolone at 5–10 mg dosage for a few weeks.
Medium-dosage of corticosteroid treatment was prednisolone at a minimum 0.2 mg/kg/day to a maximum of 0.6 mg/kg/day dosage with a slow taper.
*χ2 test.
†Logistic regression analysis.
‡Three scores mean positivity of pain, redness and swelling.
§Duration of the days from the onset to initial corticosteroid treatment.
¶A significant negative correlation.
N.D, not done due to small number or none of the patients.